Quality of life, at what cost?

Cancer Invest. 2003;21(6):965-6. doi: 10.1081/cnv-120025099.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents, Alkylating / economics
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Cost-Benefit Analysis
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / economics
  • Dacarbazine / therapeutic use
  • Drug Costs / statistics & numerical data*
  • Humans
  • Melanoma / drug therapy
  • Melanoma / economics
  • Melanoma / pathology
  • Quality of Life*
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / economics
  • Skin Neoplasms / pathology
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide